{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:03:57Z","timestamp":1793865837606,"version":"4.6.1"},"reference-count":209,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"KLH is also supported by the NIHR Manchester Biomedical Research Centre.","id":[{"id":"https:\/\/ror.org\/05njkjr15","id-type":"ROR","asserted-by":"crossref"}]},{"name":"EULAR Quality of Care Committee"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1136\/ard-2022-223335","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T13:25:17Z","timestamp":1667481917000},"page":"742-753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":244,"title":["2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E","family":"Fragoulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-3726","authenticated-orcid":false,"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6858-4338","authenticated-orcid":false,"given":"Mrinalini","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizheng Steven","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1956-2607","authenticated-orcid":false,"given":"Delphine Sophie","family":"Courvoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8394","authenticated-orcid":false,"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg MN","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes WJ","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas A","family":"Constantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garcia-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliha Crnkic","family":"Kapetanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-9009","authenticated-orcid":false,"given":"Kim","family":"Lauper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9581-7088","authenticated-orcid":false,"given":"Mariana","family":"Lu\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-3228","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jef","family":"van Rompay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1294-6421","authenticated-orcid":false,"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-022X","authenticated-orcid":false,"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-4328","authenticated-orcid":false,"given":"Annette","family":"de Thurah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223335_bib1","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3899\/jrheum.091426","article-title":"Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases?","volume":"37","author":"Stamp","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib3","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1136\/annrheumdis-2018-213045","article-title":"Response to: 'Can we prescribe TMP\/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?\u2019 by Suyama and Okada","volume":"78","author":"Park","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11926-020-0883-0","article-title":"Pneumocystis jirovecii pneumonia and other infections in idiopathic inflammatory myositis","volume":"22","author":"Mecoli","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard-2022-223335_bib5","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s10067-021-05660-4","article-title":"Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study","volume":"40","author":"Hsu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib6","first-page":"29","article-title":"Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations","volume":"9","author":"Mori","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"10.1136\/ard-2022-223335_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review Informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib9","unstructured":"Cochrane. Cochrane Handbook for systematic reviews of interventions. 6.3 ed."},{"key":"10.1136\/ard-2022-223335_bib10","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1136\/ard-2022-223335_bib11","unstructured":"Oxford centre for evidence-based Medicine\u2014Levels of evidence, 2009 [Accessed March 2022]."},{"key":"10.1136\/ard-2022-223335_bib12","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/annrheumdis-2020-218019","article-title":"Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs","volume":"79","author":"Isaacs","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/annrheumdis-2021-221490","article-title":"Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR coronavirus vaccine (COVAX) physician-reported registry","volume":"81","author":"Machado","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib14","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19868901","article-title":"When rheumatology and infectious disease come together","volume":"11","author":"Fragoulis","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223335_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-019-1997-5","article-title":"Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study","volume":"21","author":"Hsu","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223335_bib17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/acr.23426","article-title":"Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis","volume":"70","author":"Accortt","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223335_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib19","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/annrheumdis-2021-220249","article-title":"2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis","volume":"80","author":"Nikiphorou","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/annrheumdis-2020-218986","article-title":"2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice","volume":"80","author":"Ritschl","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.semarthrit.2021.03.017","article-title":"Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: results from a multi-stepped consensus-building approach","volume":"51","author":"Toupin-April","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/joim.13218","article-title":"Tuberculosis in patients with systemic lupus erythematosus-a 37-year longitudinal survey-based study","volume":"290","author":"Xiao","year":"2021","journal-title":"J Intern Med"},{"key":"10.1136\/ard-2022-223335_bib24","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/acr.23769","article-title":"Risk for herpes zoster in Tofacitinib-Treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids","volume":"71","author":"Curtis","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223335_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00296-008-0721-6","article-title":"Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus","volume":"29","author":"Lertnawapan","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223335_bib26","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S2666-5247(20)30195-6","article-title":"Globally diverse Mycobacterium tuberculosis resistance acquisition: a retrospective geographical and temporal analysis of whole genome sequences","volume":"2","author":"Ektefaie","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1136\/ard-2022-223335_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20930116","article-title":"Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors","volume":"12","author":"Evangelatos","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223335_bib28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CM9.0000000000001948","article-title":"Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials","volume":"135","author":"Ji","year":"2022","journal-title":"Chin Med J"},{"key":"10.1136\/ard-2022-223335_bib31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14740338.2020.1774550","article-title":"Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus kinases","volume":"19","author":"Cantini","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1136\/ard-2022-223335_bib32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.24476","article-title":"Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada","volume":"61","author":"Brassard","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/23744235.2019.1682187","article-title":"High risk of activation of latent tuberculosis infection in rheumatic disease patients","volume":"52","author":"Long","year":"2020","journal-title":"Infect Dis"},{"key":"10.1136\/ard-2022-223335_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(19)30012-8","article-title":"Tuberculosis in inflammatory arthritis. are biologics the only culprits?","author":"Fragoulis","year":"2019","journal-title":"Lancet Rheumatology"},{"key":"10.1136\/ard-2022-223335_bib37","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/thoraxjnl-2014-206470","article-title":"Increased risk of mycobacterial infections associated with anti-rheumatic medications","volume":"70","author":"Brode","year":"2015","journal-title":"Thorax"},{"key":"10.1136\/ard-2022-223335_bib38","first-page":"S221","author":"Targeted tuberculin testing and treatment of latent tuberculosis infection","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/ard-2022-223335_bib39","author":"Prevention CfDCa, National Center for HIV\/AIDS VH, STD, and TB Prevention, Elimination DoT"},{"key":"10.1136\/ard-2022-223335_bib40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14740338.2019.1612872","article-title":"Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice","volume":"18","author":"Cantini","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1136\/ard-2022-223335_bib41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/BOR.0000000000000493","article-title":"The interplay between tuberculosis and systemic lupus erythematosus","volume":"30","author":"Balbi","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10067-014-2817-6","article-title":"Screening of latent tuberculosis infection by interferon-\u03b3 release assays in rheumatic patients: a systemic review and meta-analysis","volume":"35","author":"Ruan","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib43","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","article-title":"Interferon-\u03b3 release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis","volume":"64","author":"Hsia","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib44","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s10156-011-0250-1","article-title":"Comparison of QuantiFERON-TB gold and the tuberculin skin test for detecting previous tuberculosis infection evaluated by chest CT findings in Japanese rheumatoid arthritis patients","volume":"17","author":"Maeda","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1136\/ard-2022-223335_bib45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5578\/tt.66122","article-title":"TST, QuantiFERON-TB gold test and T-SPOT.TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy","volume":"66","author":"Sarg\u0131n","year":"2018","journal-title":"Tuberk Toraks"},{"key":"10.1136\/ard-2022-223335_bib47","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1128\/CVI.05299-11","article-title":"Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy","volume":"18","author":"Vassilopoulos","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1136\/ard-2022-223335_bib48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1756-185X.12772","article-title":"Evaluation of interferon-gamma release assay (T-SPOT.TB(\u2122)) for diagnosis of tuberculosis infection in rheumatic disease patients","volume":"19","author":"Jiang","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib49","doi-asserted-by":"crossref","first-page":"e0119260","DOI":"10.1371\/journal.pone.0119260","article-title":"Quantiferon-Tb gold in-tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-223335_bib50","first-page":"121","article-title":"Attenuated response to PPD in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis","volume":"49","author":"Marques","year":"2009","journal-title":"Revista Brasileira de Reumatologia"},{"key":"10.1136\/ard-2022-223335_bib51","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/ibd.21605","article-title":"Prednisolone treatment affects the performance of the quantiferon gold In-Tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection","volume":"17","author":"B\u00e9lard","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/ard-2022-223335_bib52","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1177\/0961203316639381","article-title":"Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA","volume":"25","author":"Cho","year":"2016","journal-title":"Lupus"},{"key":"10.1136\/ard-2022-223335_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00408-014-9655-9","article-title":"Diagnosis of latent tuberculosis infection with T-SPOT(\u00ae).TB in a predominantly immigrant population with rheumatologic disorders","volume":"193","author":"Escalante","year":"2015","journal-title":"Lung"},{"key":"10.1136\/ard-2022-223335_bib54","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s10067-010-1532-1","article-title":"ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment","volume":"29","author":"Girlanda","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10238-009-0082-9","article-title":"Comparison of tuberculin skin test and QuantiFERON-TB gold in tube test in patients with chronic inflammatory diseases living in a tuberculosis endemic population","volume":"10","author":"Gogus","year":"2010","journal-title":"Clin Exp Med"},{"key":"10.1136\/ard-2022-223335_bib56","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1007\/s00296-011-2243-x","article-title":"Detection of latent tuberculosis infection in rheumatologic diseases before anti-TNF\u03b1 therapy: tuberculin skin test versus IFN-\u03b3 assay","volume":"32","author":"Hanta","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223335_bib57","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3899\/jrheum.090268","article-title":"Agreement between QuantiFERON-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"36","author":"Inanc","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.semarthrit.2012.07.001","article-title":"Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases","volume":"42","author":"Kim","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib59","first-page":"111","article-title":"Quantiferon TB gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents","volume":"31","author":"Klein","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib60","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3904\/kjim.2014.29.1.76","article-title":"Poor agreement between QuantiFERON-TB gold test and tuberculin skin test results for the diagnosis of latent tuberculosis infection in rheumatoid arthritis patients and healthy controls","volume":"29","author":"Lee","year":"2014","journal-title":"Korean J Intern Med"},{"key":"10.1136\/ard-2022-223335_bib61","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10067-012-1938-z","article-title":"Interferon-Gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment","volume":"31","author":"M\u00ednguez","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib62","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5114\/aoms.2013.33352","article-title":"Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-\u03b1 agents","volume":"9","author":"Paluch-Ole\u015b","year":"2013","journal-title":"Arch Med Sci"},{"key":"10.1136\/ard-2022-223335_bib63","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3899\/jrheum.090150","article-title":"Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial","volume":"36","author":"Park","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib64","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3904\/kjim.2016.222","article-title":"Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases","volume":"33","author":"Pyo","year":"2018","journal-title":"Korean J Intern Med"},{"key":"10.1136\/ard-2022-223335_bib65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3899\/jrheum.120688","article-title":"Mycobacterial interferon-gamma release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome","volume":"40","author":"Scrivo","year":"2013","journal-title":"Journal of Rheumatology"},{"key":"10.1136\/ard-2022-223335_bib66","first-page":"111","article-title":"Comparison of single and dual latent tuberculosis screening strategies before biologic and targeted therapy in patients with rheumatic diseases: a retrospective cohort study","volume":"26","author":"Tang","year":"2020","journal-title":"Hong Kong Med J"},{"key":"10.1136\/ard-2022-223335_bib67","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ejim.2011.09.001","article-title":"Should we routinely treat patients with autoimmune\/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes","volume":"22","author":"Vassilopoulos","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1136\/ard-2022-223335_bib68","first-page":"1271","article-title":"Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment","volume":"35","author":"Vassilopoulos","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib69","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-3954-y","article-title":"Diagnostic value of the interferon-gamma release assay for tuberculosis infection in patients with Behcet's disease","volume":"19","author":"Wu","year":"2019","journal-title":"BMC Infectious Diseases"},{"key":"10.1136\/ard-2022-223335_bib70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10238-010-0123-4","article-title":"A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy","volume":"11","author":"Xie","year":"2011","journal-title":"Clin Exp Med"},{"key":"10.1136\/ard-2022-223335_bib71","first-page":"246","article-title":"Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents","volume":"23","author":"So","year":"2017","journal-title":"Hong Kong Med J"},{"key":"10.1136\/ard-2022-223335_bib72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/injr.injr_66_18","article-title":"Real life experience of a screening strategy for latent tuberculosis before treatment with biologicals in Indian patients with rheumatic diseases","volume":"13","author":"Malaviya","year":"2018","journal-title":"Indian Journal of Rheumatology"},{"key":"10.1136\/ard-2022-223335_bib73","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3109\/14397595.2016.1149267","article-title":"A comparative analysis of two interferon-\u03b3 releasing assays to detect past tuberculosis infections in Japanese rheumatoid arthritis patients","volume":"26","author":"Iwagaitsu","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/ard.2008.101857","article-title":"Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis","volume":"69","author":"Martin","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00296-012-2641-8","article-title":"Screening for latent TB in patients with rheumatic disorders prior to biologic agents in a 'high-risk\u2019 TB population: comparison of two interferon gamma release assays","volume":"34","author":"Melath","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223335_bib76","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.rmed.2018.09.005","article-title":"The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea","volume":"143","author":"Kang","year":"2018","journal-title":"Respir Med"},{"key":"10.1136\/ard-2022-223335_bib77","doi-asserted-by":"crossref","first-page":"905","DOI":"10.5588\/ijtld.13.0755","article-title":"LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area","volume":"18","author":"Bonfiglioli","year":"2014","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"10.1136\/ard-2022-223335_bib78","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.reuma.2016.05.006","article-title":"How many patients with rheumatic diseases and TNF inhibitors treatment have latent tuberculosis?","volume":"13","author":"Busquets-P\u00e9rez","year":"2017","journal-title":"Reumatol Clin"},{"key":"10.1136\/ard-2022-223335_bib79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5152\/eurjrheum.2018.18096","article-title":"Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy","volume":"6","author":"Cerda","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib80","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.23705","article-title":"Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy","volume":"59","author":"Chen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib81","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s10067-020-04991-y","article-title":"Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in southern California","volume":"39","author":"Goel","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib82","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1136\/annrheumdis-2014-205376","article-title":"Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases","volume":"74","author":"Hatzara","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib83","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1128\/CVI.00049-13","article-title":"High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy","volume":"20","author":"He","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1136\/ard-2022-223335_bib84","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/s12879-020-05166-5","article-title":"Tuberculin skin test conversion in patients under treatment with anti-tumor necrotizing factor alpha agents","volume":"20","author":"Hejazi","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1136\/ard-2022-223335_bib85","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00296-019-04510-6","article-title":"Positive conversion of interferon-\u03b3 release assay in patients with rheumatic diseases treated with biologics","volume":"40","author":"Kim","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223335_bib86","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3899\/jrheum.120688","article-title":"Mycobacterial interferon-\u03b3 release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome","volume":"40","author":"Scrivo","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib87","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3346\/jkms.2014.29.8.1090","article-title":"Follow-Up testing of interferon-gamma release assays are useful in ankylosing spondylitis patients receiving anti-tumor necrosis factor alpha for latent tuberculosis infection","volume":"29","author":"Son","year":"2014","journal-title":"J Korean Med Sci"},{"key":"10.1136\/ard-2022-223335_bib88","doi-asserted-by":"crossref","first-page":"34","DOI":"10.20411\/pai.v5i1.349","article-title":"Conversion and reversion rates of tuberculosis screening assays in patients with rheumatic diseases and negative baseline screening under long-term biologic treatment","volume":"5","author":"Thomas","year":"2020","journal-title":"Pathog Immun"},{"key":"10.1136\/ard-2022-223335_bib89","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10067-016-3462-z","article-title":"The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis","volume":"36","author":"Cuomo","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib90","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3899\/jrheum.081041","article-title":"Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections","volume":"36","author":"Aggarwal","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib91","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib92","first-page":"289","article-title":"Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series","volume":"17","author":"Hern\u00e1ndez-Cruz","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib93","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/acr.21788","article-title":"Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials","volume":"65","author":"Hsia","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223335_bib94","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00508-013-0417-0","article-title":"Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis","volume":"125","author":"Kurt","year":"2013","journal-title":"Wien Klin Wochenschr"},{"key":"10.1136\/ard-2022-223335_bib95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10067-014-2495-4","article-title":"Short-Course treatment of latent tuberculosis infection in patients with rheumatic conditions proposed for anti-TNF therapy","volume":"34","author":"Valls","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib96","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2009.10.012","article-title":"Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment","volume":"77","author":"Bray","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2022-223335_bib97","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/acr.22063","article-title":"Prophylaxis for latent tuberculosis infection prior to anti\u2013tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis","volume":"65","author":"Hazlewood","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223335_bib98","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/JCMA.0000000000000071","article-title":"The T-SPOT.TB assay used for screening and monitoring of latent tuberculosis infection in patients with Beh\u00e7et's disease pre- and post-anti-TNF treatment: a retrospective study","volume":"82","author":"Shen","year":"2019","journal-title":"J Chin Med Assoc"},{"key":"10.1136\/ard-2022-223335_bib99","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1136\/ard-2022-223335_bib100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.31138\/mjr.31.1.129","article-title":"Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies","volume":"31","author":"Thomas","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib101","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5588\/ijtld.15.0283","article-title":"Risk of developing active tuberculosis in rheumatoid arthritis patients on adalimumab in Japan","volume":"20","author":"Watanabe","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1136\/ard-2022-223335_bib102","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib103","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/annrheumdis-2018-213097","article-title":"Three months of once-weekly isoniazid plus rifapentine (3Hp) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis","volume":"77","author":"Chen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib104","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/ard.61.3.251","article-title":"Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment","volume":"61","author":"Gaitonde","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib105","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/1756-185X.13376","article-title":"Biologics and risk of tuberculosis in autoimmune rheumatic diseases: a real-world clinical experience from India","volume":"22","author":"Shobha","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/injr.injr_79_18","article-title":"Prescribing patterns and safety of biologics in immune-mediated rheumatic diseases: Karnataka biologics cohort study Group experience","volume":"14","author":"Shobha","year":"2019","journal-title":"Indian Journal of Rheumatology"},{"key":"10.1136\/ard-2022-223335_bib107","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.3346\/jkms.2021.36.e70","article-title":"Risk of tuberculosis development in patients with rheumatoid arthritis receiving targeted therapy: a prospective single center cohort study","volume":"36","author":"Song","year":"2021","journal-title":"J Korean Med Sci"},{"key":"10.1136\/ard-2022-223335_bib108","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s10067-014-2528-z","article-title":"Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and\/or biologic agents","volume":"33","author":"Bourr\u00e9-Tessier","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib109","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/ard.2002.004598","article-title":"High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors","volume":"62","author":"Vanhoof","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jbspin.2020.04.010","article-title":"Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis","volume":"87","author":"Nam","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2022-223335_bib111","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/bmj.286.6369.923","article-title":"Rifampicin reduces effectiveness and bioavailability of prednisolone","volume":"286","author":"McAllister","year":"1983","journal-title":"Br Med J"},{"key":"10.1136\/ard-2022-223335_bib112","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cld.883","article-title":"Reactivation of hepatitis B virus: a review of clinical guidelines","volume":"15","author":"Myint","year":"2020","journal-title":"Clin Liver Dis"},{"key":"10.1136\/ard-2022-223335_bib113","doi-asserted-by":"crossref","first-page":"e001035","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations","volume":"5","author":"Rondaan","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223335_bib114","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/acr.23346","article-title":"Risk of hepatitis B virus reactivation in patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs: a systematic review and meta-analysis","volume":"70","author":"Lin","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223335_bib115","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1007\/s10067-018-4096-0","article-title":"Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis","volume":"37","author":"Su","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib116","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5152\/eurjrheum.2015.0111","article-title":"Current antiviral practice and course of hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study)","volume":"2","author":"Kalyoncu","year":"2015","journal-title":"Eur J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib117","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-008-0790-6","article-title":"Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders","volume":"29","author":"Kalyoncu","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223335_bib118","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/0961203317711009","article-title":"Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study","volume":"27","author":"Lin","year":"2018","journal-title":"Lupus"},{"key":"10.1136\/ard-2022-223335_bib119","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/14397595.2017.1419842","article-title":"Hepatitis B virus reactivation in patients with rheumatoid arthritis: a single-center study","volume":"28","author":"Matsuzaki","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib120","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/1471-2474-15-449","article-title":"Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice","volume":"15","author":"Mo","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1136\/ard-2022-223335_bib121","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10067-012-1988-2","article-title":"Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs","volume":"31","author":"Tan","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib122","article-title":"High risk of viral reactivation in hepatitis B patients with systemic lupus erythematosus","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ard-2022-223335_bib123","first-page":"320","article-title":"Clinical outcomes of low-dose leflunomide for rheumatoid arthritis complicated with hepatitis B virus carriage and safety observation","volume":"31","author":"Ming-Xu","year":"2015","journal-title":"Pak J Med Sci"},{"key":"10.1136\/ard-2022-223335_bib124","first-page":"566","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment","volume":"215","author":"Chen","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1136\/ard-2022-223335_bib125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874312902115010039","article-title":"Effect of low-dose corticosteroid use on HBV reactivation in HBsAg-positive rheumatoid arthritis patients","volume":"15","author":"Jeong","year":"2021","journal-title":"The Open Rheumatology Journal"},{"key":"10.1136\/ard-2022-223335_bib126","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13010","article-title":"Short-Course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation","volume":"20","author":"Chen","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib127","first-page":"25","article-title":"No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study","volume":"31","author":"Giardina","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib128","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s10620-020-06725-1","article-title":"Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing Tocilizumab-Containing treatment","volume":"66","author":"Kuo","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1136\/ard-2022-223335_bib129","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy","volume":"70","author":"Lan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib130","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/acr.22786","article-title":"Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection","volume":"68","author":"Padovan","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223335_bib131","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","article-title":"Long-Term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"69","author":"Vassilopoulos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib132","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10067-013-2385-1","article-title":"Anti-TNF therapy in patients with HBV infection\u2013analysis of 87 patients with inflammatory arthritis","volume":"33","author":"Ye","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib133","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3899\/jrheum.081246","article-title":"Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature","volume":"36","author":"Zingarelli","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib134","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10067-012-1960-1","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF\u03b1 agents: a retrospective analysis of 49 cases","volume":"31","author":"Ryu","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib135","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/1756-185X.14217","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib","volume":"24","author":"Wang","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib136","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study","volume":"77","author":"Chen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib137","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American gastroenterological association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1136\/ard-2022-223335_bib138","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20912646","article-title":"Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations","volume":"12","author":"Koutsianas","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223335_bib139","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cld.2019.04.012","article-title":"Screening and prophylaxis to prevent hepatitis B reactivation: other populations and newer agents","volume":"23","author":"Sasadeusz","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1136\/ard-2022-223335_bib140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.27716","article-title":"Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection","volume":"62","author":"Barone","year":"2015","journal-title":"Hepatology"},{"key":"10.1136\/ard-2022-223335_bib141","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2016-209973","article-title":"Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan","volume":"76","author":"Fukuda","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib142","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13075-019-2053-1","article-title":"Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese red cross Hospital","volume":"21","author":"Fukuda","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223335_bib143","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12072-014-9597-6","article-title":"Long-Term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients","volume":"9","author":"Laohapand","year":"2015","journal-title":"Hepatol Int"},{"key":"10.1136\/ard-2022-223335_bib144","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s10067-018-4295-8","article-title":"Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients","volume":"37","author":"Schwaneck","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib145","doi-asserted-by":"crossref","first-page":"926836","DOI":"10.1155\/2014\/926836","article-title":"Hbv reactivation in patients treated with antitumor necrosis factor-alpha (TNF-\u03b1) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis","volume":"2014","author":"Cantini","year":"2014","journal-title":"Int J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib146","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3899\/jrheum.120052","article-title":"Do low titers of antibody against hepatitis B surface antigen carry a risk of viral reactivation during immunosuppressive therapy for rheumatic diseases?","volume":"39","author":"Mori","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib147","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.cgh.2020.03.039","article-title":"Low but long-lasting risk of reversal of seroconversion in patients with rheumatoid arthritis receiving immunosuppressive therapy","volume":"18","author":"Chen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1136\/ard-2022-223335_bib148","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/s10165-010-0337-z","article-title":"Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients","volume":"21","author":"Urata","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib149","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.20130","article-title":"Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative\/anti-hepatitis B core antigen positive) with rheumatic diseases","volume":"62","author":"Caporali","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223335_bib150","doi-asserted-by":"crossref","first-page":"R179","DOI":"10.1186\/ar2868","article-title":"Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients","volume":"11","author":"Charpin","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223335_bib151","first-page":"93","article-title":"Long-Term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study","volume":"35","author":"Giannitti","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib152","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3899\/jrheum.090436","article-title":"Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases","volume":"37","author":"Kim","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib153","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1756-185X.13513","article-title":"2018 update of the APLAR recommendations for treatment of rheumatoid arthritis","volume":"22","author":"Lau","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib154","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"2021","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, European association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1136\/ard-2022-223335_bib156","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.berh.2019.03.008","article-title":"Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases","volume":"32","author":"Mok","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib157","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1136\/ard-2022-223335_bib158","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/1756-185X.13582","article-title":"Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: a long-term, real-world observation","volume":"22","author":"Chen","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib159","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41598-020-59406-4","article-title":"Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-\/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2022-223335_bib160","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/1756-185X.13401","article-title":"Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"22","author":"Watanabe","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib161","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13075-018-1748-z","article-title":"Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study","volume":"20","author":"Tien","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223335_bib162","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2021-220774","article-title":"Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease","volume":"80","author":"Chen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib163","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3899\/jrheum.110289","article-title":"Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases","volume":"38","author":"Kato","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib164","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5152\/eurjrheum.2015.150072","article-title":"Viral hepatitis screening guideline before biological drug use in rheumatic patients","volume":"3","author":"Karada\u011f","year":"2016","journal-title":"Eur J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib165","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jbspin.2017.05.013","article-title":"Italian consensus guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis","volume":"84","author":"Sebastiani","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2022-223335_bib166","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":"Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223335_bib167","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-013-2378-0","article-title":"Long-Term safety of anti-TNF-\u03b1 in PSA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib168","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","article-title":"Anti-Tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection","volume":"51","author":"Parke","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib169","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/RHU.0000000000000536","article-title":"Retrospective study of patients on etanercept therapy for rheumatic diseases in patients with chronic hepatitis C virus","volume":"23","author":"Gandhi","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib171","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223335_bib172","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14397595.2018.1558918","article-title":"Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis","volume":"29","author":"Sebastiani","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib173","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1177\/0961203315571465","article-title":"Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy","volume":"24","author":"Chen","year":"2015","journal-title":"Lupus"},{"key":"10.1136\/ard-2022-223335_bib174","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10067-015-2962-6","article-title":"Tumor necrosis factor-\u03b1 antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study","volume":"34","author":"Lin","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib175","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1517\/14712598.2015.1011616","article-title":"Current evidence in the field of the management with TNF-\u03b1 inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection","volume":"15","author":"Caso","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1136\/ard-2022-223335_bib176","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/ard.2009.117200","article-title":"European League against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies","volume":"69","author":"Mosca","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib177","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib178","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/rheumatology\/kex189","article-title":"Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy","volume":"57","author":"Cates","year":"2018","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223335_bib179","doi-asserted-by":"crossref","first-page":"162","DOI":"10.55563\/clinexprheumatol\/cpu6r9","article-title":"Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review","volume":"40","author":"Winthrop","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.berh.2013.01.004","article-title":"Infections in vasculitis","volume":"27","author":"Guillevin","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib181","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1136\/annrheumdis-2020-217092","article-title":"Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020","volume":"79","author":"Lortholary","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03009742.2020.1850854","article-title":"Reduction of Pneumocystis jirovecii pneumonia and bloodstream infections by trimethoprim-sulfamethoxazole prophylaxis in patients with rheumatic diseases","volume":"50","author":"Honda","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib183","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13075-019-1996-6","article-title":"Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223335_bib184","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/PL00021707","article-title":"Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy","volume":"15","author":"Ogawa","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib186","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"41","author":"Vananuvat","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib187","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11926-017-0664-6","article-title":"Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented?","volume":"19","author":"Wolfe","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard-2022-223335_bib188","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar4472","article-title":"Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study","volume":"16","author":"Katsuyama","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223335_bib189","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1445-5994.2007.01382.x","article-title":"Audit of Pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period","volume":"37","author":"Meuli","year":"2007","journal-title":"Intern Med J"},{"key":"10.1136\/ard-2022-223335_bib190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.reuma.2020.02.006","article-title":"Pneumocystis jirovecii in immunocompromised patients with rheumatic diseases","volume":"17","author":"Vela Casasempere","year":"2021","journal-title":"Reumatol Clin"},{"key":"10.1136\/ard-2022-223335_bib191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2020.1812834","article-title":"The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with rheumatic diseases","volume":"31","author":"Harada","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib192","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/s10165-012-0730-x","article-title":"A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases","volume":"23","author":"Takenaka","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib193","doi-asserted-by":"crossref","first-page":"rkaa029","DOI":"10.1093\/rap\/rkaa029","article-title":"An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up","volume":"4","author":"Utsunomiya","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"10.1136\/ard-2022-223335_bib194","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-016-1206-8","article-title":"Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial","volume":"19","author":"Utsunomiya","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223335_bib195","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/14397595.2015.1112467","article-title":"Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus: a retrospective cohort study","volume":"26","author":"Suyama","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib196","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1136\/annrheumdis-2019-215009","article-title":"Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib197","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1136\/annrheumdis-2018-213027","article-title":"Can we prescribe TMP\/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?","volume":"78","author":"Suyama","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib198","article-title":"Prophylaxis against Pneumocystis pneumonia in rheumatoid arthritis patients treated with b\/tsDMARDs: insights from 3,787 cases in first registry","author":"Sonomoto","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223335_bib199","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00296-021-04945-w","article-title":"Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of Pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids","volume":"42","author":"Jinno","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223335_bib200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jiac.2019.01.005","article-title":"Efficacies of atovaquone, pentamidine, and trimethoprim\/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"25","author":"Kitazawa","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1136\/ard-2022-223335_bib201","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.semarthrit.2018.10.018","article-title":"Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs","volume":"48","author":"Schmajuk","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223335_bib202","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/annrheumdis-2021-222006","article-title":"EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update","volume":"81","author":"Landew\u00e9","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib203","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib204","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"Update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"2019","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib205","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/annrheumdis-2012-202228","article-title":"Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of Listeria and Salmonella infections in the UK","volume":"72","author":"Davies","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib206","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.rdc.2017.06.009","article-title":"Central nervous system infections associated with immunosuppressive therapy for rheumatic disease","volume":"43","author":"Bradshaw","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard-2022-223335_bib207","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2217\/17460816.2.6.567","article-title":"Opportunistic infections associated with TNF-\u00ce\u00b1 treatment","volume":"2","author":"Orenstein","year":"2007","journal-title":"Fut Rheumatol"},{"key":"10.1136\/ard-2022-223335_bib208","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223335_bib209","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/annrheumdis-2019-215803","article-title":"EULAR recommendations for the generic core competences of health professionals in rheumatology","volume":"79","author":"Edelaar","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T05:23:50Z","timestamp":1749792230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724083870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":209,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0003496724083870"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223335","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}